Back to Search
Start Over
Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device
- Source :
- The Journal of Thoracic and Cardiovascular Surgery. (2):384-385
- Publisher :
- American Association for Thoracic Surgery. Published by Mosby, Inc.
-
Abstract
- Bleeding is the most frequent complication related to implantation of a mechanical cardiac assist device. 1 Recombinant activated factor VII (NovoSeven; Novo Nordisk, Bagsvaerd, Denmark) was developed as a prohemostatic agent. We report the successful use of recombinant activated factor VII to control bleeding abnormalities in a patient with a left ventricular assist device (LVAD). Clinical Summary
- Subjects :
- Adult
Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
medicine.medical_treatment
Factor VIIa
law.invention
chemistry.chemical_compound
law
Artificial heart
Activated factor VII
Humans
Medicine
Cardiac assist
Chemotherapy
Factor VII
business.industry
Blood Coagulation Disorders
Recombinant Proteins
Surgery
chemistry
Ventricular assist device
Recombinant DNA
Heart-Assist Devices
business
Complication
Cardiology and Cardiovascular Medicine
Subjects
Details
- Language :
- English
- ISSN :
- 00225223
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- The Journal of Thoracic and Cardiovascular Surgery
- Accession number :
- edsair.doi.dedup.....314218f5e25c75927f9aee367bc08351
- Full Text :
- https://doi.org/10.1067/mtc.2002.119328